NEAT1_1 confers gefitinib resistance in lung adenocarcinoma through promoting AKR1C1-mediated ferroptosis defence

Shuman Zhen,Yunlong Jia,Yan Zhao,Jiali Wang,Boyang Zheng,Tianxu Liu,Yuqing Duan,Wei Lv,Jiaqi Wang,Fan Xu,Yueping Liu,Yi Zhang,Lihua Liu
DOI: https://doi.org/10.1038/s41420-024-01892-w
2024-03-13
Cell Death Discovery
Abstract:Gefitinib is one of the most extensively utilized epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) for treating advanced lung adenocarcinoma (LUAD) patients harboring EGFR mutation. However, the emergence of drug resistance significantly compromised the clinical efficacy of EGFR-TKIs. Gaining further insights into the molecular mechanisms underlying gefitinib resistance holds promise for developing novel strategies to overcome the resistance and improve the prognosis in LUAD patients. Here, we identified that the inhibitory efficacy of gefitinib on EGFR-mutated LUAD cells was partially dependent on the induction of ferroptosis, and ferroptosis protection resulted in gefitinib resistance. Among the ferroptosis suppressors, aldo-keto reductase family 1 member C1 (AKR1C1) exhibited significant upregulation in gefitinib-resistant strains of LUAD cells and predicted poor progression-free survival (PFS) and overall survival (OS) of LUAD patients who received first-generation EGFR-TKI treatment. Knockdown of AKR1C1 partially reversed drug resistance by re-sensitizing the LUAD cells to gefitinib-mediated ferroptosis. The decreased expression of miR-338-3p contributed to the aberrant upregulation of AKR1C1 in gefitinib-resistant LUAD cells. Furthermore, upregulated long non-coding RNA (lncRNA) nuclear paraspeckle assembly transcript 1_1 (NEAT1_1) sponged miR-338-3p to neutralize its suppression on AKR1C1. Dual-luciferase reporter assay and miRNA rescue experiment confirmed the NEAT1_1/miR-338-3p/AKR1C1 axis in EGFR-mutated LUAD cells. Gain- and loss-of-function assays demonstrated that the NEAT1_1/miR-338-3p/AKR1C1 axis promoted gefitinib resistance, proliferation, migration, and invasion in LUAD cells. This study reveals the effects of NEAT1_1/miR-338-3p/AKR1C1 axis-mediated ferroptosis defence in gefitinib resistance in LUAD. Thus, targeting NEAT1_1/miR-338-3p/AKR1C1 axis might be a novel strategy for overcoming gefitinib resistance in LUAD harboring EGFR mutation.
cell biology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is: **To explore how long - non - coding RNA NEAT1_1 leads to gefitinib resistance in lung adenocarcinoma by promoting the AKR1C1 - mediated ferroptosis defense mechanism**. ### Background Gefitinib is an epidermal growth factor receptor - tyrosine kinase inhibitor (EGFR - TKIs) widely used in the treatment of patients with advanced lung adenocarcinoma (LUAD) carrying EGFR mutations. However, the emergence of drug resistance significantly weakens the clinical efficacy of EGFR - TKIs. A deep understanding of the molecular mechanisms of gefitinib resistance is expected to develop new strategies to overcome resistance and improve the prognosis of LUAD patients. ### Research questions 1. **Molecular mechanisms of gefitinib resistance**: The study found that the inhibitory effect of gefitinib on EGFR - mutated LUAD cells is partly dependent on inducing ferroptosis, and ferroptosis protection leads to gefitinib resistance. 2. **The role of AKR1C1 in gefitinib resistance**: In gefitinib - resistant LUAD cell lines, AKR1C1 is significantly up - regulated and is associated with poor progression - free survival (PFS) and overall survival (OS) in LUAD patients. 3. **The role of the NEAT1_1/miR - 338 - 3p/AKR1C1 axis**: The study further revealed that NEAT1_1 up - regulates AKR1C1 by sponging miR - 338 - 3p, thereby promoting gefitinib resistance, proliferation, migration and invasion. ### Main findings - **Ferroptosis and gefitinib resistance**: The inhibitory effect of gefitinib is partly dependent on inducing ferroptosis, and ferroptosis protection leads to gefitinib resistance. - **Up - regulation of AKR1C1**: In gefitinib - resistant LUAD cell lines, AKR1C1 is significantly up - regulated and is associated with poor prognosis in LUAD patients. - **NEAT1_1/miR - 338 - 3p/AKR1C1 axis**: NEAT1_1 up - regulates AKR1C1 by sponging miR - 338 - 3p, thereby promoting gefitinib resistance, proliferation, migration and invasion. ### Conclusion This study reveals the important role of the NEAT1_1/miR - 338 - 3p/AKR1C1 axis in gefitinib resistance, providing new potential targets for overcoming gefitinib resistance.